Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Teva Pharmaceuticals is undergoing a strategic transformation from a leading global generics company to a leading biopharma company, initiated three years ago with a pivot to growth strategy [2][3] - The company has faced skepticism regarding its growth strategy but has executed a clear plan year-on-year, leading to significant progress in its transition [3] Company Strategy - The pivot to growth strategy was designed to return Teva to growth and fundamentally transform its business model [2] - The CEO emphasized the importance of this strategy in positioning Teva as a world-leading biopharma company [3]